UBE2B, ubiquitin conjugating enzyme E2 B, 7320

N. diseases: 59; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE In this study, we developed an innovative approach in preventing HCV infection using a synergistic combination of a broadly neutralizing human monoclonal antibody (HMAb) targeting the HCV E2 protein and a host-targeting anti-claudin 1 (CLDN1) humanized monoclonal antibody. 30599173 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression disease BEFREE Expression of HCV E2 protein in 293 cells was confirmed by western blot analysis. rAAV2/8.HCV E2 vaccine or rAAV2/rh32.33.HCV E2 vaccine was intramuscularly injected into C57BL/6 mice. 30569131 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE HCV E2 protein when associated with CD81 may be responsible for B cell lymphoproliferative disorders, as extrahepatic manifestation. 31755827 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Constructs of GrAD and both of its permutated forms fused with the initially insoluble N-terminal fragment of hepatitis C virus' E2 protein were tested. 31636289 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Moreover, selective neutralizing human monoclonal antibodies (HuMAbs) targeting conserved antigenic domain B and D epitopes of the E2 protein bound strongly to the HCV VLPs, suggesting that these critical epitopes are expressed on the surface of the particles. 29691437 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Intrinsic structural versatility of the highly conserved 412-423 epitope of the Hepatitis C Virus E2 protein. 29758309 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Acquisition of resistance to bNAbs by some autologous strains was accompanied by progressive loss of E2 protein function, and temporally associated with HCV clearance. 30439341 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE In this regard, we have studied the mechanism underlying the HCV fusion process using liposomes and a truncated form of E2 protein lacking the transmembrane region, E2<sub>661</sub> (amino acids 384-661). 29273334 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE HCV E2 protein mimicked GPC3 and led to enhanced Hippo activity and decreased YAP in cultured normal human hepatocytes. 29577937 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE HCV Core protein has been associated with the modulation of potentially oncogenic cellular processes and E2 protein has been useful in evolutive studies to analyze the diversity of HCV. 27163636 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Antigenic determinants generating the neutralizing antibodies from these two samples were delineated by epitope mapping using the core, E1 and E2 regions and a stretch of 45 amino acid peptide (E2C45) derived from the C-terminal region of HCV-E2 protein (aa 634-679) was designed. 28221101 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Previous studies have indicated that interactions between the HCV E2 protein and CD81 on host cells are required for HCV infection. 28481946 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Human thyroid cell lines ML-1 and human thyrocytes in primary cell culture were treated with HCV recombinant E2 protein. 27860532 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Present data also suggest that the strict conservation of Gly436 in E2 protein of different HCV genotypes is likely dictated by structural restraints. 26973093 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE HC33.4 and AR4A are two of the most potent anti-HCV human bNAbs characterized to date, binding to highly conserved epitopes near the amino- and carboxy-terminus of HCV envelope (E2) protein, respectively. 28235087 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression disease BEFREE Re-exposure of convalescent (cured) B cells to viremic plasma and recombinant HCV E2 protein led to re-expression of T-bet. 27925349 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Using HCV-like particles (HCV-LPs) corresponding to genotype 3a (prevalent in India), we obtained three mAbs specific for the E2 protein that significantly inhibited virus binding to hepatoma cells. 27574733 2016
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Immunoprecipitation analysis revealed that AP1S3 interacted with the HCV E2 protein. 27079945 2016
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE These cells proliferated prominently through the early expression of interleukin-10 and intracellular latent membrane protein (LMP)-l. By contrast, the overexpression of CD81 on EBV-transformed B cells by anti-CD81 mAb or HCV E2 protein induced apoptosis through reactive oxygen species (ROS)-mediated mitochondrial dysfunction. 26498453 2015
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Surface plasmon resonance detection was used to screen the ligand set for binding to recombinant E2 protein, and the best binders were subsequently tested to identify compounds that inhibit the infection of Huh-7 cells by HCV. 25357246 2014
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Similar results were obtained for the other HIV-1 proteins Vif and Vpr, whereas no differences were obtained in the number of epitopes for the hepatitis C virus E1/E2 protein sequence or for the scrambled HIV-1 sequence. 24954875 2014
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression disease BEFREE The aim of this study was to evaluate and compare the inflammatory response of endothelial cells to two recombinant forms of the HCV E2 protein produced in different expression systems (Escherichia coli and Pichia pastoris). 25317702 2014
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Specifically, a novel host factor CD63 was shown to directly interact with HCV E2 protein. 23593195 2013
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Our mutagenesis analyses of HCV pseudoparticles and cell culture-derived HCV using the H77 isolate indicate that five residues at positions 14, 15, and 25-27 mediate binding of the E2 protein to the scavenger receptor class B, type I receptor, and any residue herein is indispensable for HCV cell entry. 22927442 2012
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Hepatitis C virus E2 protein involve in insulin resistance through an impairment of Akt/PKB and GSK3β signaling in hepatocytes. 22721429 2012